Physician profile
Michael Ammann
NPI 1932264843
$3,532.08
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $791 · 2021: $658 · 2022: $790 · 2023: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $498.66 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $416.50 | 2019-2023 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $409.77 | 2019-2023 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.83 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $312.21 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $232.90 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $143.51 | 2022-2023 | |
| Pfizer INC. | $135.30 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $126.02 | 2019-2022 | |
| Astellas Pharma US INC | $124.14 | 2019-2022 | |
| Amarin Pharma, INC. | $116.86 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $107.12 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $86.96 | 2023 | Gemtesa |
| Radius Health, INC. | $53.51 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $51.66 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $44.46 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $43.45 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.32 | 2019 | |
| Abbott Laboratories | $41.89 | 2021-2022 | |
| Boston Scientific Corporation | $33.27 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $32.22 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $26.63 | 2022 | |
| Mylan Specialty L.P. | $26.17 | 2020-2022 | |
| Abbvie INC. | $24.38 | 2023 | Vraylar |
| Esperion Therapeutics, INC. | $23.06 | 2021 | |
| Merck Sharp & Dohme LLC | $19.03 | 2020 | |
| Eisai INC. | $17.98 | 2020 | |
| Phadia US INC. | $14.27 | 2022 | |
| Cook Medical LLC | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ammann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.